Regardless, the use of a single PSA test is gradually fading, and it will eventually be replaced with a test of the combined multiple tumor biomarkers, which is becoming a major trend in the diagnosis and assessment of the treatment effectiveness of prostate cancer [4]. The gene discussed is KLK3; the disease is prostate carcinoma.